Edition:
United States

Nicox SA (NCOX.PA)

NCOX.PA on Paris Stock Exchange

9.94EUR
8 Dec 2017
Change (% chg)

€0.02 (+0.16%)
Prev Close
€9.93
Open
€9.98
Day's High
€9.99
Day's Low
€9.77
Volume
128,046
Avg. Vol
352,426
52-wk High
€13.68
52-wk Low
€7.65

Latest Key Developments (Source: Significant Developments)

Bausch + Lomb and Nicox announces FDA approval of Vyzulta
Thursday, 2 Nov 2017 04:05pm EDT 

Nov 2 (Reuters) - Valeant Pharmaceuticals International Inc :Bausch + Lomb and Nicox announce FDA approval of Vyzulta™ (latanoprostene Bunod Ophthalmic Solution), 0.024%.Valeant - ‍co's wholly owned subsidiary, Bausch + Lomb and Nicox S.A announced FDA approved NDA for Vyzulta​.  Full Article

Nicox says ‍cash balance was 47.1 million euros as of Sept. 30
Tuesday, 24 Oct 2017 01:30am EDT 

Oct 24 (Reuters) - NICOX SA ::‍CASH BALANCE OF EUR 47.1 MILLION AS OF SEPTEMBER 30, 2017​.Q3 NO REVENUE ‍​ VERSUS NO REVENUE YEAR AGO.  Full Article

Nicox and pSivida enter collaboration agreement to develop sustained release drug for glaucoma patients​
Tuesday, 10 Oct 2017 01:31am EDT 

Oct 10 (Reuters) - Nicox SA :Nicox-Co and pSivida enter strategic collaboration agreement to develop sustained release drug to lower intraocular pressure in patients with glaucoma​.Would make additional payments for any incremental development activities for each implant formulation product candidate.Expected payments from Nicox associated with agreement are not considered material to Nicox's financial statements at this time​.Says ‍pSivida will be responsible for initial development activities of ocular insert formulations, for which it will receive undisclosed sums​.  Full Article

Nicox and pSivida enter strategic collaboration agreement
Tuesday, 10 Oct 2017 01:30am EDT 

Oct 10 (Reuters) - NICOX SA ::REG-NICOX AND PSIVIDA ENTER STRATEGIC COLLABORATION AGREEMENT TO DEVELOP SUSTAINED RELEASE DRUG TO LOWER INTRAOCULAR PRESSURE IN PATIENTS WITH GLAUCOMA.NEW INTELLECTUAL PROPERTY FROM THE COLLABORATION RELATING TO THE DRUG-DEVICE COMBINATION WILL BE JOINTLY OWNED‍​.PSIVIDA TO BE RESPONSIBLE FOR INITIAL DEVELOPMENT ACTIVITIES OF OCULAR INSERT FORMULATIONS, FOR WHICH IT WILL RECEIVE UNDISCLOSED SUMS BY NICOX‍​.  Full Article

Nicox announces licensing agreement with Eyevance
Thursday, 21 Sep 2017 01:30am EDT 

Sept 21 (Reuters) - NICOX SA ::ANNOUNCES LICENSING AGREEMENT WITH EYEVANCE FOR COMMERCIALIZATION OF ZERVIATETM IN UNITED STATES.‍TO RECEIVE $6 MILLION UPFRONT PAYMENT AND UP TO AN ADDITIONAL $42.5 MILLION IN FUTURE MILESTONES, PLUS 8-15% IN TIERED ROYALTIES​.EYEVANCE TARGETS U.S. LAUNCH OF ZERVIATE IN LATE 2018.  Full Article

Nicox H1 operating loss narrows to ‍​11.6 million euros
Friday, 8 Sep 2017 01:30am EDT 

Sept 8 (Reuters) - NICOX SA ::‍ZERVIATE (CETIRIZINE OPHTHALMIC SOLUTION), 0.24% NEW DRUG APPLICATION (NDA) APPROVED​.H1 OPERATING LOSS EUR ‍​11.6 MILLION VERSUS LOSS OF EUR 12.7 MILLION YEAR AGO.‍INVESTIGATIONAL NEW DRUG (IND) SUBMISSIONS FOR NCX 470 FOR IOP LOWERING AND NCX 4251 FOR BLEPHARITIS PLANNED FOR H1​.H1 NET LOSS OF THE YEAR EUR 12.2‍​ MILLION VERSUS LOSS OF EUR 24.2 MILLION YEAR AGO.‍BAUSCH + LOMB RESPONDED TO VYZULTA (LATANOPROSTENE BUNOD OPHTHALMIC SOLUTION), 0.024% COMPLETE RESPONSE LETTER (CRL) RECEIVED FROM FDA​.REPORTS H1 NO REVENUE VERSUS EUR 9,000 YEAR AGO.NET LOSS FROM CONTINUING OPERATIONS EUR 12.2 MILLION AS OF JUNE 30, 2017, VERSUS NET LOSS OF EUR 12.9 YEAR AGO.‍CASH, CASH EQUIVALENTS OF EUR 20.4 MILLION AS OF JUNE 30, 2017, COMPARED TO EUR 28.9 MILLION ON DECEMBER 31, 2016​.  Full Article

NicOx raises $31 million in private placement of shares
Friday, 18 Aug 2017 02:49am EDT 

Aug 18 (Reuters) - NICOX SA ::ANNOUNCED ON THURSDAY A PRIVATE PLACEMENT OF SHARES TO RAISE EUR 26.25 MILLION (USD 30.97 MILLION).  Full Article

Nicox lists 3.5 million new shares on Euronext Paris
Wednesday, 16 Aug 2017 06:24am EDT 

Aug 16 (Reuters) - EURONEXT::NICOX SA TO LIST 3.5 MILLION NEW SHARES ON EURONEXT PARIS AS OF AUGUST 17; REFERENCE PRICE: EUR 7.5.  Full Article

Nicox announces 26.25 million euros financing
Tuesday, 15 Aug 2017 01:30am EDT 

Aug 15 (Reuters) - NICOX SA ::NICOX ANNOUNCES €26.25 MILLION FINANCING.NICOX SA - ‍RESERVED CAPITAL INCREASE OF ORDINARY SHARES OF COMPANY TO A SPECIFIC CATEGORY OF INVESTORS​.NICOX - ‍TO USE NET PROCEEDS TO FINANCE NICOX'S RESEARCH AND DEVELOPMENT OF PIPELINE CANDIDATES, WORKING CAPITAL.​.  Full Article

Nicox launches capital increase of 597,897 euros following FDA's approval of Zerviate
Friday, 9 Jun 2017 01:45am EDT 

June 9 (Reuters) - NICOX SA ::ANNOUNCED ON THURSDAY ISSUING AND ADMISSION TO TRADING ON THE EURONEXT REGULATED MARKET IN PARIS OF 597,897 NEW SHARES AWARDED TO EXISTING ACIEX SHAREHOLDERS FOLLOWING THE US FDA'S APPROVAL OF ZERVIATE.CAPITAL INCREASE OF NOMINAL AMOUNT OF EUR 597,897.  Full Article

BRIEF-Bausch + Lomb and Nicox announces FDA approval of Vyzulta

* Bausch + Lomb and Nicox announce FDA approval of Vyzulta™ (latanoprostene Bunod Ophthalmic Solution), 0.024%